- Personal FinanceCompare Online BrokersTop StocksAlternative Investing
- CryptoGet StartedNFTs
eFFECTOR Therapeutics (NASDAQ:EFTR), Quotes and News Summary
eFFECTOR Therapeutics (NASDAQ: EFTR)
Earnings
see more| Q3 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-11-07 | ||||||
| REV | |||||||
| Q2 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -3.830 | -0.170 | 3.6600 | ||||
| REV | 520.000K | 2.011M | 1.491M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
eFFECTOR Therapeutics Questions & Answers
You can purchase shares of eFFECTOR Therapeutics (NASDAQ: EFTR) through any online brokerage.
Other companies in eFFECTOR Therapeutics’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Brooklyn (NASDAQ:BTX), Humanigen (NASDAQ:HGEN) and Applied Genetic (NASDAQ:AGTC).
The latest price target for eFFECTOR Therapeutics (NASDAQ: EFTR) was reported by Credit Suisse on Thursday, March 17, 2022. The analyst firm set a price target for 14.00 expecting EFTR to rise to within 12 months (a possible 2047.24% upside). 10 analyst firms have reported ratings in the last year.
The stock price for eFFECTOR Therapeutics (NASDAQ: EFTR) is $0.652 last updated August 9, 2022, 8:00 PM UTC.
There are no upcoming dividends for eFFECTOR Therapeutics.
eFFECTOR Therapeutics’s Q3 earnings are confirmed for Monday, November 7, 2022.
There is no upcoming split for eFFECTOR Therapeutics.
eFFECTOR Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.